yil-781 and Diabetes-Mellitus--Type-2

yil-781 has been researched along with Diabetes-Mellitus--Type-2* in 1 studies

Other Studies

1 other study(ies) available for yil-781 and Diabetes-Mellitus--Type-2

Article	Year
Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity. Bioorganic & medicinal chemistry letters, 2012, Mar-15, Volume: 22, Issue:6 Substituted azaquinazolinones were identified as antagonists of the GHSr-1A receptor for the treatment of type II diabetes and obesity. Optimisation for potency and LogD lead to the identification of orally bioavailable, potent antagonists with improved selectivity over hERG. Topics: Administration, Oral; Animals; Aza Compounds; Biological Availability; Diabetes Mellitus, Type 2; Drug Design; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Kinetics; Male; Obesity; Quinazolinones; Rats; Rats, Sprague-Dawley; Receptors, Ghrelin; Structure-Activity Relationship	2012

Article

Year

Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity.

Bioorganic & medicinal chemistry letters, 2012, Mar-15, Volume: 22, Issue:6

Substituted azaquinazolinones were identified as antagonists of the GHSr-1A receptor for the treatment of type II diabetes and obesity. Optimisation for potency and LogD lead to the identification of orally bioavailable, potent antagonists with improved selectivity over hERG.

Topics: Administration, Oral; Animals; Aza Compounds; Biological Availability; Diabetes Mellitus, Type 2; Drug Design; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Kinetics; Male; Obesity; Quinazolinones; Rats; Rats, Sprague-Dawley; Receptors, Ghrelin; Structure-Activity Relationship

2012